嘉事堂: 关于修订公司章程及其附件的公告

Core Viewpoint - The company, Jiasitang Pharmaceutical Co., Ltd., has revised its Articles of Association to enhance corporate governance and compliance with regulatory requirements [1][2]. Summary by Relevant Sections Corporate Governance - The revision includes the addition of a section on independent directors to clarify their responsibilities and duties [1][2]. - A new chapter on the specialized committees of the board has been introduced to define their roles and responsibilities more clearly [1][2]. Terminology Adjustments - The term "shareholders' meeting" has been changed to "shareholders' assembly" throughout the document [1][2]. Compliance and Regulatory Updates - The revisions align with the Company Law of the People's Republic of China, the Guidelines for Articles of Association of Listed Companies, and the Shenzhen Stock Exchange Listing Rules [1][2]. - Outdated regulatory references have been removed from the Articles [1][2]. Operational Changes - The position of Chief Executive Officer has been removed, and the powers of the President have been refined [1][2]. - New provisions have been added regarding the reporting obligations if a shareholders' assembly cannot be held on time [2]. Future Actions - The proposed amendments will be submitted for approval at the second extraordinary general meeting of shareholders in 2025, after which the company will proceed with the necessary business registration procedures [2].